# US 2012/0251519 A1 · Endopeptidase Treatment of Smooth Muscle Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251519 A1
- Document ID: US20120251519A1
- Status: Published application
- Kind: A1
- Application number: 13/432,323
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Allergan, Inc.
- Inventors: Andrew M. BLUMENFELD; Mitchell F. Brin
- Web page: https://patentgrep.com/patent/US20120251519A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- C07K 14/33: from Clostridium (G)
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a smooth muscle disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs in treating a smooth muscle disorder, and use of such TEMs and Clostridial toxins in treating a smooth muscle disorder.

## Claims

### Claim 1

A method of treating a smooth muscle disorder in an individual, the method comprising the step of administering to the individual in need thereof a therapeutically effective amount of a composition including a TEM comprising a targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain, and wherein administration of the composition reduces a symptom of the smooth muscle disorder, thereby treating the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TEM comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain, the Clostridial toxin translocation domain, the targeting domain, 2) the Clostridial toxin enzymatic domain, the targeting domain, the Clostridial toxin translocation domain, 3) the targeting domain, the Clostridial toxin translocation domain, and the Clostridial toxin enzymatic domain, 4) the targeting domain, the Clostridial toxin enzymatic domain, the Clostridial toxin translocation domain, 5) the Clostridial toxin translocation domain, the Clostridial toxin enzymatic domain and the targeting domain, or 6) the Clostridial toxin translocation domain, the targeting domain and the Clostridial toxin enzymatic domain.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Clostridial toxin translocation domain is a BoNT/A translocation domain, a BoNT/B translocation domain, a BoNT/C1 translocation domain, a BoNT/D translocation domain, a BoNT/E translocation domain, a BoNT/F translocation domain, a BoNT/G translocation domain, a TeNT translocation domain, a BaNT translocation domain, or a BuNT translocation domain.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Clostridial toxin enzymatic domain is a BoNT/A enzymatic domain, a BoNT/B enzymatic domain, a BoNT/C1 enzymatic domain, a BoNT/D enzymatic domain, a BoNT/E enzymatic domain, a BoNT/F enzymatic domain, a BoNT/G enzymatic domain, a TeNT enzymatic domain, a BaNT enzymatic domain, or a BuNT enzymatic domain.

### Claim 5 (depends on 1)

The method of claim 1, wherein the smooth muscle disorder is a blood vessel disorder, a respiratory tract disorder, a digestive system disorder, or an urinary tract disorder.

### Claim 6 (depends on 1)

The method of claim 1, wherein the blood vessel disorder is a vasoconstriction, a vasodilation, an atherosclerosis, an arteriolosclerosis, or a vasculitis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the respiratory tract disorder is a bronchoconstriction, a bronchospasm, an asthma, or a COPD.

### Claim 8 (depends on 1)

The method of claim 1, wherein the digestive system disorder is achalasia, Chagas disease, chronic anal fissure, ineffective peristalsis, irritable bowel syndrome, a spastic motility disorder, or a sphincter of Oddi dysfunction.

### Claim 9 (depends on 1)

The method of claim 1, wherein the urinary tract disorder is an urinary incontinence, a detrusor dysfunction, an overactive bladder, a lower urinary tract dysfunction, a urinary retention, a urinary hesitancy, a polyuria, or a nocturia.

### Claim 10

A method of treating a smooth muscle disorder in an individual, the method comprising the step of administering to the individual in need thereof a therapeutically effective amount of a composition including a TEM comprising a targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain, and wherein administration of the composition reduces a symptom of the smooth muscle disorder, thereby treating the individual.

### Claim 11 (depends on 10)

The method of claim 10, wherein the smooth muscle disorder is a blood vessel disorder, a respiratory tract disorder, a digestive system disorder, or an urinary tract disorder.

### Claim 12 (depends on 11)

The method of claim 11, wherein the blood vessel disorder is a vasoconstriction, a vasodilation, an atherosclerosis, an arteriolosclerosis, or a vasculitis.

### Claim 13 (depends on 11)

The method of claim 11, wherein the respiratory tract disorder is a bronchoconstriction, a bronchospasm, an asthma, or a COPD.

### Claim 14 (depends on 11)

The method of claim 11, wherein the digestive system disorder is achalasia, Chagas disease, chronic anal fissure, ineffective peristalsis, irritable bowel syndrome, a spastic motility disorder, or a sphincter of Oddi dysfunction.

### Claim 15 (depends on 11)

The method of claim 11, wherein the urinary tract disorder is an urinary incontinence, a detrusor dysfunction, an overactive bladder, a lower urinary tract dysfunction, a urinary retention, a urinary hesitancy, a polyuria, or a nocturia.

### Claim 16

A use of a TEM in the manufacturing a medicament for treating a smooth muscle disorder in an individual in need thereof, wherein the TEM comprising a targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain.
